On June 9, ImmunityBio rose 5.06% in regular trading, trading at $7.2777/share, with trading volume of $47.51 million. The stock had pulled back since late May on profit-taking after multiple catalysts were priced in, and this rebound appears tied to continued digestion of recent clinical milestones.

On the news front, the company recently presented two posters and one online abstract at the ASCO annual meeting, showcasing latest Phase III clinical data for its IL-15 receptor agonist immunotherapy ANKTIVA in non-small cell lung cancer and bladder cancer. Additionally, INBRX-106 reported mid-Phase II data in first-line head and neck squamous cell carcinoma, with the combination arm achieving a confirmed objective response rate of 44.0% among 25 patients versus 21.4% among 28 patients in the control arm. Furthermore, the CSCO Urothelial Carcinoma Treatment Guidelines have incorporated ANKTIVA combined with BCG as a novel bladder-sparing treatment option, reinforcing its commercial outlook for patients who have failed standard therapy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)